Pharmacologic approaches to therapy for vasovagal syncope (Q33145116)

22 July 2017

1 reference

title

Pharmacologic approaches to therapy for vasovagal syncope (English)

1 reference

22 July 2017

0 references

0 references

Calkins H

1

1 reference

22 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

American Journal of Cardiology

22 July 2017

published in

1 reference

22 July 2017

volume

84

1 reference

22 July 2017

issue

8A

1 reference

22 July 2017

page(s)

20Q-25Q

1 reference

Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope

22 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Oral fluid therapy. A promising treatment for vasodepressor syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Response of neurocardiac syncope to beta-blocker therapy: interaction between age and parasympathetic tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: correlation with successful therapy with beta-receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Efficacy of pindolol for treatment of vasovagal syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Efficacy of Different Treatment Strategies for Neurocardiogenic Syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Effects of fludrocortisone on sympathetic nerve activity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Midodrine: a role in the management of neurocardiogenic syncope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

The use of methylphenidate in the treatment of refractory neurocardiogenic syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Beneficial effects of dextro-amphetamine in the treatment of vasodepressor syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope -- a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Exacerbations of neurally mediated syncope associated with sertraline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Usefulness of transdermal scopolamine for vasovagal syncope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Clinical efficacy of propantheline bromide in neurocardiogenic syncope: pharmacodynamic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

Excessive myocardial contraction in vasovagal syncope demonstrated by echocardiography during head-up tilt test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900626-8

10.1016/S0002-9149(99)00626-8

7 January 2021

Identifiers

DOI

1 reference

22 July 2017

1 reference